FOSTER CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer ...
– Results highlight PPMP as a tool for identifying most promising drug combinations for patients in high unmet medical needs, including JMML – JMML is a rare, aggressive pediatric malignancy for which ...
FOSTER CITY, Calif. and KANSAS CITY, Mo., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical-stage therapeutic platform company developing predictive precision ...
FOSTER CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs”), a clinical-stage therapeutics platform company developing a new class of cancer ...
Despite significant advancement in the treatment of acute lymphoblastic leukemia (ALL), overall survival in adult ALL is at most 50% and progression rates in high risk pediatric ALL remain between 20 ...
– Article Published in November 9th Issue of ASCO’s Journal of Clinical Oncology Precision Oncology (JCO PO) – – Results highlight PPMP as a tool for identifying most promising drug combinations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results